241 results about "Vasodilation" patented technology

This invention relates to a new type of apparatus designed to modulate the neurovegetative system and integrate the neurovegetative action with that of the central nervous system. The method is not invasive, because it uses pulses transmitted through the skin; the intensity of the stimulus is controlled directly by the patient in order to achieve better integration with the central nervous system. This invention effectively treats vascular disorders resulting from obstruction of the arteries of the legs, heart and brain because it induces vasodilatation and increases blood flow and the production of new blood vessels. The method also improves lesions of the spinal column, especially those affecting the back and neck, and other orthopaedic disorders.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing direct current electricity. Electrodes are used to deliver a direct current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, perdiodontitis, and oral malodor while also promoting general oral hygiene.

The specification discloses purine nucleotide analogues which modulate cardiac muscle contractility and possess vasodilator activity. In addition, related methods of administration and the identity of receptors that bind these compounds are disclosed.

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

A negative pressure, thermal energy device has an enclosure that receives a patient's body part. The body part is positioned in the enclosure and contacts a thermal energy contacting surface. The thermal energy contacting surface transfers its thermal energy to the body part. While in the enclosure, the body part is also exposed to a negative pressure to cause vasodilation. The combination of the vasodilation and the thermal energy transfer alter the patient's body core temperature. To ensure the body part remains in contact with the thermal contacting surface, the enclosure has a portion thereof that moves when negative pressure is in the enclosure. When the negative pressure is applied, the deforming enclosure material is pulled toward the body part to provide a positive pressure on the body part that ensures the body part effectively contacts the thermal energy contacting surface.

The invention discloses a magnetic resonance angiography method. The magnetic resonance angiography method includes applying a flowing sensitive dispersed phase gradient magnetic field in the readout direction and / or the phase encoding direction and / or the layer selection direction in a vasoconstriction period and then applying a residual magnetic moment removing gradient magnetic field after the flowing sensitive dispersed phase gradient magnetic field is applied; collecting blood flow images in the vasoconstriction period; collecting blood flow images in a vasodilatation period; and carrying out subtraction on the blood flow images in the vasoconstriction period and the blood flow images in the vasodilatation period to obtain blood flow images. The invention further discloses a magnetic resonance angiography system. According to the magnetic resonance angiography method and the magnetic resonance angiography system, in the specific implementation method, the flowing sensitive dispersed phase is used in the vasoconstriction period imaging process, so that intra-arterial self-spin dispersed phase can significantly lower arterial blood signals, and therefore the influence on imaging due to the velocity and the direction of blood flow can be reduced, high-quality peripheral arterial images can be obtained, and clinical practicability of the non-enhanced magnetic resonance angiography technology is improved.

The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth in a mammalian host. In specific embodiments, the compounds are useful in the treatment of congestive heart failure.

Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising:wherein dashed lines independently represent either a single or a double bond, R1 is a lower alkyl, R2 is a lower alkyl, R3 is a lower alkyl or halogen, R4 is a lower alkyl or hydrogen, R5 is a lower alkyl or hydrogen, R6 is a hydrogen, lower alkyl or halogen, and R7 is a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.

The present invention relates to a pad for treating skin diseases, comprising agar gel and a fiber layer fixed to the inside of the gel, and a manufacturing method therefor. The pad of the present invention inhibits blood vessel exudation symptoms according to vasodilation by maintaining a low temperature of the affected area, reduces an itchy sensation and, at the same time, removes, from the skin, plasma proteins and various plasma-derived substances accumulated in skin tissue, thereby having an effect of alleviating the symptoms of the affected area.

Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and / or promote neuroregeneration.

The present invention is a powerful vasodilatation and transdermal penetration system, which quickly penetrates the dermis of the skin and deposits beneficial ingredients at the subcutaneous layer, which then stimulates the capillary blood flow to fat cells and increases the metabolizing process of fat cells and cellulite, thereby reducing the size of fat cells, thus creating a smoother appearance to the surface of the skin as well as reducing the appearance of the size of the affected area.

The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Apparatus and methods are provided for treating a human condition by providing an appendage chamber having a thermal exchange member. A vacuum may be applied to the appendage chamber to maintain vasodilation of an appendage when placed within the appendage chamber. The appendage may be heated or cooled at the thermal exchange member for therapeutic application of thermal energy to treat a number of circulatory, neurological, lymphatic, or endocrinal maladies.

A system for providing an early risk recognition monitoring by measurement of a peripheral tissue perfusion of a patient instead of clinically significant changes in systemic blood pressure and / or blood flow comprises a wristband device for gathering measurement data of the patient. The device measures a first temperature (t1) of the patient at the first wrist (or distal antebrachium) point and a second temperature (t2) of the patient at the second finger point, whereupon the system determines altered peripheral tissue perfusion by determining temperature gradient (Δt) between said first and second points. If the gradient (Δt) exceeds or deceeds a predetermined range, the system construes the exceeding as a peripheral vasoconstriction and the deceeding as a peripheral vasodilatation, and thereby provides a first early risk recognition phase (p1) and transmits it as a warning indication to end devices of health care personnel.